![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » Axonics Acquires Contura and Its Urethral Bulking Agent for $200 Million
Axonics Acquires Contura and Its Urethral Bulking Agent for $200 Million
Irvine, Calif-based Axonics Modulation Technologies has purchased Contura for $200 million, a move that earns it the company’s flagship product Bulkamid, a urethral bulking agent.
Bulkamid is a hydrogel injected into the urethral wall in a minimally invasive office or outpatient procedure to restore the urethra’s natural closing pressure. It is used as a treatment for stress urinary incontinence (SUI).
SUI is a condition often associated with childbirth and is prevalent among women of all ages, including an estimated 20 million in the U.S. alone.
Upcoming Events
-
18Jul
-
21Oct